2023年11月25日～2023年12月1日の間に収集した論文情報を追加しました。
1. An Updated Comprehensive Pharmacovigilance Study of Drug-Induced Thrombocytopenia based on FDA Adverse Event Reporting System Data.
FAERSデータを用いた薬剤誘発性血小板減少症の包括的な解析
対象DB：FAERS
2. Ocular Surface Adverse Events are not Associated with Dupilumab use in Nasal Polyp Treatment.
慢性副鼻腔炎治療におけるデュピルマブによる眼表反応の関連
対象DB：FAERS
3. Narrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events.
FDAの規制不足により、栄養補助食品の悪影響が増加
対象DB：FAERS
4. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS).
IgEやT2サイトカインを対象としたモノクローナル抗体治療で寄生虫感染の安全性シグナル
対象DB：FAERS
5. The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database.
免疫チェックポイント阻害剤治療中のがん患者でのアスピリン使用と免疫関連の副作用の関連性
対象DB：FAERS
6. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis.
PDE5阻害剤の勃起不全治療で報告された重大な副作用を調査
対象DB：FAERS
7. Strong opioids-induced cardiac, neurologic, and respiratory disorders: a real-world study from 2004 to 2023 based on FAERS.
FAERSデータでオピオイドの報告リスク解析
対象DB：FAERS
8. Serotonin syndrome: A pharmacovigilance comparative study of drugs affecting serotonin levels.
セロトニン症候群のFAERSデータ解析でSSRIが最多報告、MAO阻害薬も高い報告比
対象DB：FAERS
9. A real-world analysis of safety profile of selexipag by using FDA adverse event Reporting System (FAERS).
セレキシパグの281の副作用シグナルを同定
対象DB：FAERS
10. Association of Cardiovascular Events with COVID-19 Vaccines using Vaccine Adverse Event Reporting System (VAERS): A Retrospective Study.
COVID-19ワクチンと心血管イベントの関連性を調査
対象DB：FAERS,VAERS
11. Association of Antipsychotic Drugs with Venous Thromboembolism: Data Mining of Food and Drug Administration Adverse Event Reporting System and Mendelian Randomization Analysis.
静脈血栓塞栓症の抗精神病薬関連の信頼性についての研究
対象DB：FAERS
12. Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).
デノスマブとゾレドロン酸のAEの強度比較
対象DB：FAERS
13. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
サシツズマブゴビテカンにおける血液リンパ系および肝胆系障害のリスクの研究
対象DB：FAERS
14. Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study.
免疫チェックポイント阻害剤治療に伴う血液およびリンパ系有害事象をFAERSから解析
対象DB：FAERS
15. Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system.
COVID-19治療薬モルヌピラビルのFAERSデータから有害事象を抽出
対象DB：FAERS
16. Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System.
新規口内チロシンキナーゼ阻害剤の神経精神系有害事象をFAERSデータから評価
対象DB：FAERS
17. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022.
希少疾病における人道的使用の特徴と効果を評価
対象DB：FAERS
18. New exploration of signal detection of Regional Risks from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China.
ZAERSデータベースからの情報を用いて、薬剤のリスクを検出。特にアレルギー関連リスクの精度向上と漢方薬のラベル改善が示唆
対象DB：FAERS
19. Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse event Reporting system.
SGLT-2阻害剤と尿路感染症・生殖器真菌感染の関連性をFAERSデータベースで調査
対象DB：FAERS
20. A Real-World Data Driven Pharmacovigilance Investigation on Drug-Induced Arrhythmia Using KAERS DB, a Korean Nationwide Adverse Drug Reporting System.
韓国の副作用報告データベースでの薬剤誘発性不整脈の有病率、重症度、予測因子の調査
対象DB：FAERS,KAERS
21. Analysis of Opioid-Related Adverse Events in Japan Using FAERS Database.
日本で承認されたオピオイドに関連する副作用をFDAのデータから分析
対象DB：FAERS
22. Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system.
JADERデータを用いた抗精神病薬と悪性症候群の関連を解析
対象DB：JADER
23. Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases.
プロトンポンプ阻害薬とオキサリプラチン誘発性末梢神経障害の影響を2つのデータベースで調査
対象DB：JADER
24. Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database.
免疫チェックポイント阻害剤による下垂体関連の有害事象に関するJADERデータベースの調査
対象DB：JADER
25. Skin Toxicities Associated with Botulin Toxin Injection for Aesthetic Procedures: Data from the European Spontaneous Reporting System.
A型ボツリヌス毒素の皮膚毒性に関する研究
対象DB：EudraVigilance
26. A Pharmacovigilance Study Regarding the Risk of Antibiotic-Associated Clostridioides difficile Infection Based on Reports from the EudraVigilance Database: Analysis of Some of the Most Used Antibiotics in Intensive Care Units.
EudraVigilanceからの報告に基づく偽膜性大腸炎関連の抗生物質使用に関する分析
対象DB：EudraVigilance
27. Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database.
妊娠中や授乳中の多発性硬化症患者における薬剤の安全性を比較
対象DB：EudraVigilance
28. Short-term outcomes of pancreatoduodenectomy in older individuals over a 9-year period using real-world data: A multilevel analysis based on a nationwide administrative database in Japan.
高齢者における膵十二指腺切除術（PD）の短期的な結果を評価
対象DB：DPC
29. Perioperative Use of Intravenous Levodopa as an Anti-Parkinsonian Drug: A Propensity Score Analysis.
胃または大腸がん手術中のパーキンソン病患者に対する経口抗パーキンソン薬の中止と予後の研究
対象DB：DPC
30. Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan.
日本における中等度から重度の乾癬（PsO）患者のIL-阻害剤治療の中止および切り替え傾向を評価
対象DB：JMDC
31. Prevalence and incidence of strabismus by age group in Japan: A nationwide population-based cohort study.
斜視の全体的な有病率や発生率、年齢別の割合を調査
対象DB：NDB
32. Analysis of the Association Between the Number of Intensivists and the Use of Cardiovascular Agonists: An Ecological Study Using Data From National Databases of Japan.
日本の保険請求データを用いて、心血管アゴニストの使用と集中治療医の数の関連性を調査
対象DB：NDB
33. Real-world clinical outcomes of oral anticoagulants among Japanese patients with atrial fibrillation and concomitant coronary artery disease.
日本の心房細動（AF）と冠動脈疾患（CAD）患者を対象に、ワルファリン、ダビガトラン、リバーロキサバンの抗凝固薬の主要出血リスクを比較
対象DB：MDV
34. Trends in cardiac rehabilitation rates among patients admitted for acute heart failure in Japan, 2009-2020.
日本の急性心不全（AHF）患者の病院内および外来における心臓リハビリ（CR）利用傾向を調査
対象DB：MDV
35. Association of Antipsychotic Drugs with the Risk of Recurrent Venous Thromboembolism: A Retrospective Study of Data from a Japanese Inpatient Database.
MDVを使った抗精神病薬の使用と再発性静脈血栓塞栓症のリスクを評価
対象DB：MDV
36. Symptoms and signs in patients with heart failure: association with 3-month hospitalisation and mortality.
新たに心不全（HF）と診断された患者の初回入院と死亡との関連性を検討
対象DB：CPRD
37. Estimating the cost and epidemiology of mild to severe chronic pain associated with osteoarthritis in England: a retrospective analysis of linked primary and secondary care data.
変形性関節症に関連した慢性疼痛の医療費とリソース利用を検証
対象DB：CPRD
38. Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink.
虚血性心疾患および高LDLコレステロール患者の12か月MACEおよび非心血管死亡率を推定
対象DB：CPRD
39. Incident Comorbidity, Resource Use, and All-Cause Mortality Associated with Prurigo Nodularis: A United Kingdom Retrospective Database Analysis.
結節性痒疹患者の患状、リソース利用、死亡率を調査
対象DB：CPRD
40. Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK.
COPD患者における初回増悪のリスク要因を調査
対象DB：CPRD
41. A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD.
慢性閉塞性肺疾患（COPD）患者の経口コルチコステロイド（OCS）使用と非使用を比較する研究
対象DB：CPRD
42. Chronic Low Back Pain with and without Concomitant Osteoarthritis: A Retrospective, Longitudinal Cohort Study of Patients in England.
慢性腰痛（CLBP）と骨関節炎（OA）に関連する中等度から重度の疼痛の経済的負担を調査
対象DB：CPRD
43. Fracture patterns in adult onset type 1 diabetes and associated risk factors - A nationwide cohort study.
新たに診断された比較的健康な1型糖尿病患者の骨折リスクを調査
対象DB：CPRD
44. Gender differences in spontaneous adverse event reports associated with zolpidem in South Korea, 2015-2019.
ゾルピデムの副作用に性差が見られる可能性を韓国のデータで調査
対象DB：KAERS